Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599525 | 1.00 | KDM4E (0.37) | KDM4EGRIK1PTGS1AKR1C3 | |
| SCHEMBL28154184 | 0.82 | KDM4E (0.32) | KDM4E | |
| SCHEMBL6726481 | 0.82 | KDM4E (0.32) | KDM4E | |
| SCHEMBL14675185 | 0.79 | PTGS1 (0.31) | GRIK1PTGS1AKR1C3 | |
| SCHEMBL3621930 | 0.79 | PTGS1 (0.31) | GRIK1PTGS1AKR1C3 | |
| SCHEMBL1469906 | 0.79 | PTGS1 (0.31) | GRIK1PTGS1AKR1C3 | |
| SCHEMBL28321184 | 0.78 | — | — | |
| SCHEMBL1924255 | 0.77 | PTGS1 (0.30) | PTGS1AKR1C3 | |
| SCHEMBL1142234 | 0.77 | HMGCR (0.32) | PTGS1AKR1C3 | |
| SCHEMBL30828310 | 0.77 | HMGCR (0.42) | KDM4EPTGS1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108601741-A | galenic formulations of organic compounds | 诺华股份有限公司 | 2018-09-28 | — | — | CN | claimed |
| EP-3089736-A1 | PHARMACEUTICAL COMPOSITIONS FOR POORLY WATER-SOLUBLE COMPOUNDS | Ascendia Pharmaceuticals, LLC (US) | 2016-11-09 | — | — | EP | claimed |
| WO-2015103230-A9 | PHARMACEUTICAL COMPOSITIONS FOR POORLY WATER-SOLUBLE COMPOUNDS | ASCENDIA PHARMACEUTICALS, LLC (US) | 2015-10-22 | — | — | WO | claimed |
| WO-2015103230-A1 | PHARMACEUTICAL COMPOSITIONS FOR POORLY WATER-SOLUBLE COMPOUNDS | ASCENDIA PHARMACEUTICALS, LLC (US) | 2015-07-09 | — | — | WO | claimed |
| EP-2588106-A2 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION CONTAINING PRAMIPEXOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF WITH IMPROVED STABILITY | Hyundai Pharm Co., Ltd. (KR) | 2013-05-08 | — | — | EP | claimed |
| CN-101001615-B | Drug delivery product and method | NEXMED HOLDINGS INC | 2012-07-04 | — | — | CN | claimed |
| WO-2012002644-A2 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION CONTAINING PRAMIPEXOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF WITH IMPROVED STABILITY | HYUNDAI PHARM CO., LTD. (KR) | 2012-01-05 | — | — | WO | claimed |
| US-20090053304-A1 | Composition and method of producing a taste masking formulation of laxatives for bowel cleaning preparation prior to colonoscopy | CHEN JINLING | 2009-02-26 | — | — | US | claimed |
| WO-2008068731-A1 | EXTENDED RELEASE FORMULATIONS OF CARVEDILOL | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2008-06-12 | — | — | WO | claimed |
| US-20080139496-A1 | COMBINATION THERAPY FOR REDUCTION OF TOXICITY OF CHEMOTHERAPEUTIC AGENTS | CASCADE ESTATE LTD. (GB) | 2008-06-12 | — | — | US | claimed |
| US-20080138404-A1 | EXTENDED RELEASE FORMULATIONS OF CARVEDILOL | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2008-06-12 | — | — | US | claimed |
| CN-101001615-A | Drug delivery product and method | NEXMED HOLDINGS INC (US) | 2007-07-18 | — | — | CN | claimed |
| EP-1478349-A1 | A METHOD FOR RELEASING NANOSIZED PARTICLES OF AN ACTIVE SUBSTANCE FROM A DIFFUSION-CONTROLLED PHARMACEUTICAL COMPOSITION FOR ORAL USE | Amarin Development AB (SE) | 2004-11-24 | — | — | EP | claimed |
| US-20030215513-A1 | Method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use | AMARIN DEVELOPMENT AB (SE) | 2003-11-20 | — | — | US | claimed |
| WO-2003070225-A1 | A METHOD FOR RELEASING NANOSIZED PARTICLES OF AN ACTIVE SUBSTANCE FROM A DIFFUSION-CONTROLLED PHARMACEUTICAL COMPOSITION FOR ORAL USE | AMARIN DEVELOPMENT AB (SE) | 2003-08-28 | — | — | WO | claimed |
| WO-2000033796-A1 | DEVICE, METHOD, AND COMPOSITION FOR SKIN CLEANSING | LAVIPHARM LABORATORIES, INC. (US) | 2000-06-15 | — | — | WO | claimed |
| US-20260091050-A1 | ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY | Atea Pharmaceuticals, Inc. (US) | 2026-04-02 | — | — | US | disclosed |
| US-12551499-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-0277128-A1 | TONER PARTICLES FOR ELECTROPHOTOGRAPHIC COPYING AND PROCESSES FOR THEIR PREPARATION. | CASCO NOBEL AB (SE) | 1988-08-10 | — | — | EP | disclosed |
| WO-1987001828-A1 | TONER PARTICLES FOR ELECTROPHOTOGRAPHIC COPYING AND PROCESSES FOR THEIR PREPARATION | CASCO NOBEL AB (SE) | 1987-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551499-B2 | Highly active compounds against COVID-19 | PNP, SLC29A2, MTAP | KDM4E 1494/4885GRIK1 4396/4885PTGS1 2253/4885 |
| US-20260091050-A1 | ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY | SLC10A1, SLC10A2, STAT3 | KDM4E 1899/4885GRIK1 4811/4885PTGS1 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.